Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Frontiers in Oncology|September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA NetworkGiorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.
Cancer|June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML CampusValentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
British Journal of Haematology|October 12, 2021
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML reportMassimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Blood Advances|December 24, 2019
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WPMichele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Pageof 15